Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-149725

Chief Development Officer sold 360 shares at $34.90 ($12,564)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Yeleswaram Krishnaswamy Chief Development Officer 2026-04-08 Sale 10b5-1 −360 $34.90 $12,564 286,516 D: show line 1 in the form
Open-market sales · 360 sh · avg $34.90 · $12,564
Loading xslF345X06/ownership.xml…